HER-2 positive

P1/2, N=24, Terminated, Institut Paoli-Calmettes | N=106 --> 24 | Suspended --> Terminated; Drug development withdrawn

P1/2, N=36, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Suspended --> Active, not recruiting

P=N/A, N=2200, Active, not recruiting, Spotlight Medical

P=N/A, N=1000, Recruiting, Société Algérienne de Formation et Recherche en Oncologie

The HER2 inhibitors represent different mechanisms of actions, including trastuzumab, pertuzumab, tucatinib, and lapatinib, all of which are clinically approved, as well as PEPDG278D, a recombinant human protein which was previously shown to induce the degradation of HER2 and epidermal growth factor receptor (EGFR). Despite p95HER2 expression and resistance to current HER2 inhibitors, HER2-positive BC cells and tumors are highly vulnerable to PEPDG278D-induced degradation of HER2 and EGFR. By inducing HER2 degradation, PEPDG278D eliminates p95HER2 in HER2-positive BC cells and tumors.

Response to NACT is strongly influenced by ER expression, tumor grade, and sTIL levels. Composite profiles combining these factors can help identify patients most likely to achieve meaningful response, while also highlighting subgroups with low benefit where alternative treatment strategies may be more appropriate.

No changes in the LVEF or GLS that required treatment interruption occurred, and cardiac biomarkers remained normal. Among patients with HER2-positive early-stage breast cancer who received paclitaxel and trastuzumab, had a preserved baseline LVEF, and had no anthracycline exposure, the cardiotoxicity incidence was low, suggesting that cardiac monitoring may be simplified in this population.

The combination of APCP and Exo-Mens demonstrated synergistic anti-tumor effects in HER2+ BC cells by targeting pathways related to angiogenesis, proliferation, and apoptosis. In this context, the upregulation of miR-422a suggests a potential tumor-suppressive role, warranting further investigation.

In a routine public oncology setting with limited resources, the use of SC trastuzumab was associated with clear advantages in terms of efficiency and the treatment experience while also mitigating the workload of infusion areas. These results provide practical, context-specific evidence that could help healthcare systems to improve the organization of oncology services and make better use of scarce hospital resources.

P=N/A, N=2000, Not yet recruiting, Hebei Medical University Fourth Hospital

Standardized BI-RADS breast MRI descriptors demonstrate consistent and independent associations with established pathological biomarkers and molecular subtypes. Although MRI does not replace tissue-based assessment, these imaging phenotypes may provide complementary biological context and support radiopathological correlation in multidisciplinary care. Given the retrospective, single-center design with single-reader assessment and absence of external validation, these findings should be interpreted with appropriate caution and require prospective multicenter confirmation before clinical implementation.

In this cN + cohort, approximately one in six patients eligible for AST had residual disease only in the axilla. Less-invasive axillary staging procedures were associated with a low estimated theoretical risk of missed AST eligibility. However, these findings should be interpreted in light of the modest sample size.